Literature DB >> 18160526

Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis.

Nathan P Wiederhold1, Laura K Najvar, Ana C Vallor, William R Kirkpatrick, Rosie Bocanegra, Destiny Molina, Marcos Olivo, John R Graybill, Thomas F Patterson.   

Abstract

Serum (1-->3)-beta-D-glucan concentrations were serially measured in the presence and absence of antifungal therapy in a murine model of invasive pulmonary aspergillosis. Serum (1-->3)-beta-D-glucan was detected early during the course of infection, and reductions in this biomarker were associated with improved survival in animals treated with antifungal agents.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18160526      PMCID： PMC2258522          DOI： 10.1128/AAC.01425-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.

Authors:  Johan Maertens; Koen Theunissen; Gregor Verhoef; Johnny Verschakelen; Katrien Lagrou; Eric Verbeken; Alexander Wilmer; Jan Verhaegen; Marc Boogaerts; Johan Van Eldere
Journal:  Clin Infect Dis       Date:  2005-09-29       Impact factor: 9.079

2.  Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections.

Authors:  Jerry W Pickering; Howard W Sant; Catherine A P Bowles; William L Roberts; Gail L Woods
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

3.  Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay.

Authors:  Kieren A Marr; Michel Laverdiere; Anja Gugel; Wendy Leisenring
Journal:  Clin Infect Dis       Date:  2005-05-05       Impact factor: 9.079

4.  Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients.

Authors:  D Caillot; L Mannone; B Cuisenier; J F Couaillier
Journal:  Clin Microbiol Infect       Date:  2001       Impact factor: 8.067

5.  Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery.

Authors:  D Caillot; O Casasnovas; A Bernard; J F Couaillier; C Durand; B Cuisenier; E Solary; F Piard; T Petrella; A Bonnin; G Couillault; M Dumas; H Guy
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

6.  Novel inhalational murine model of invasive pulmonary aspergillosis.

Authors:  Donald C Sheppard; Gunter Rieg; Lisa Y Chiang; Scott G Filler; John E Edwards; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis.

Authors:  Carlos A Alvarez; Nathan P Wiederhold; Jason T McConville; Jay I Peters; Laura K Najvar; John R Graybill; Jacqueline J Coalson; Robert L Talbert; David S Burgess; Rosie Bocanegra; Keith P Johnston; Robert O Williams
Journal:  J Infect       Date:  2007-03-13       Impact factor: 6.072

8.  Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.

Authors:  Zekaver Odabasi; Gloria Mattiuzzi; Elihu Estey; Hagop Kantarjian; Fumihiro Saeki; Richard J Ridge; Paul A Ketchum; Malcolm A Finkelman; John H Rex; Luis Ostrosky-Zeichner
Journal:  Clin Infect Dis       Date:  2004-06-28       Impact factor: 9.079
  8 in total
  11 in total

1.  Post-diagnostic kinetics of the (1 → 3)-β-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia.

Authors:  S Koo; L R Baden; F M Marty
Journal:  Clin Microbiol Infect       Date:  2012-03-08       Impact factor: 8.067

2.  Serum (1->3)-β-D-glucan measurement in coccidioidomycosis.

Authors:  George R Thompson; Derek J Bays; Suzanne M Johnson; Stuart H Cohen; Demosthenes Pappagianis; Malcolm A Finkelman
Journal:  J Clin Microbiol       Date:  2012-06-12       Impact factor: 5.948

3.  Inhaled voriconazole for prevention of invasive pulmonary aspergillosis.

Authors:  Justin A Tolman; Nathan P Wiederhold; Jason T McConville; Laura K Najvar; Rosie Bocanegra; Jay I Peters; Jacqueline J Coalson; John R Graybill; Thomas F Patterson; Robert O Williams
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

4.  Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis.

Authors:  Nathan P Wiederhold; Laura K Najvar; Satoru Matsumoto; Rosie A Bocanegra; Monica L Herrera; Brian L Wickes; William R Kirkpatrick; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

Review 5.  Antifungal pharmacokinetics and pharmacodynamics.

Authors:  Alexander J Lepak; David R Andes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

6.  The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.

Authors:  William W Hope; Vidmantas Petraitis; Ruta Petraitiene; Tamarra Aghamolla; John Bacher; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

7.  Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans.

Authors:  Scott W Mueller; Tyree H Kiser
Journal:  Curr Fungal Infect Rep       Date:  2011-03-26

8.  Evaluation of the efficacies of Amphotericin B, Posaconazole, Voriconazole, and Anidulafungin in a murine disseminated infection by the emerging opportunistic Fungus Sarocladium (Acremonium) kiliense.

Authors:  Fabiola Fernández-Silva; Javier Capilla; Emilio Mayayo; Deanna A Sutton; Pilar Hernández; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

9.  Prognostic Potential of the Panfungal Marker (1 → 3)-β-D-Glucan in Invasive Mycoses Patients.

Authors:  P Pini; C Venturelli; M Girardis; F Forghieri; E Blasi
Journal:  Mycopathologia       Date:  2018-07-02       Impact factor: 2.574

10.  Real-time nucleic acid sequence-based amplification to predict the clinical outcome of invasive aspergillosis.

Authors:  Si-Hyun Kim; Chulmin Park; Eun-Young Kwon; Na-Young Shin; Jae-Cheol Kwon; Sun Hee Park; Su-Mi Choi; Dong-Gun Lee; Jung-Hyun Choi; Jin-Hong Yoo
Journal:  J Korean Med Sci       Date:  2011-12-19       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.